1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Biocon And Eris Strike Indian Deal Over Branded Formulations

The Deal Will See Over 430 Biocon Employees Move To Eris Lifesciences

 
• By Adam Zamecnik

Biocon has announced a deal with fellow Indian pharma firm Eris Lifesciences that involves the sale of its local metabolics, oncology, and critical care products while also transferring its employees.

Two Businessmen Shaking Hands With Flag of India
• Source: Shutterstock

Biocon Biologics has entered into a long-term commercial collaboration deal with pharma company Eris Lifesciences that features the sale of Biocon’s metabolics, oncology, and critical care products in the Indian market, for a total transaction value of INR12.4bn ($149m).

Over 430 Biocon employees will be moved to Eris as part of the portfolio transfer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.